PRVB Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2023 @ 22:00):

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases...

Stats
Tagesvolumen	9.12M
Durchschnittsvolumen	2.84M
Marktkapitalisierung	2.38B
EPS	$0 ( 2024-03-27 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-16.43
ATR14	$0.594 (2.38%)

Insider Trading

Date	Person	Action	Amount	type
2023-04-27	Sessa Capital (master), L.p.	Sell	15 567 497	Common Stock
2023-04-27	Wysenski Nancy	Sell	128 981	Option to Purchase Common Stock
2023-04-27	Wysenski Nancy	Sell	22 200	Option to Purchase Common Stock
2023-04-27	Wysenski Nancy	Sell	23 000	Option to Purchase Common Stock
2023-04-27	Wysenski Nancy	Sell	33 000	Option to Purchase Common Stock

INSIDER POWER
-62.73
Last 100 transactions
Buy: 11 373 023 \| Sell: 48 540 195

Volumen Korrelation

Lang: 0.34 (neutral)

Kurz: 0.37 (neutral)

Signal:(80.187) Neutral

Provention Bio Inc Korrelation

10 Am meisten positiv korreliert
KRBP	0.886
RICO	0.879
NETE	0.825
MMAC	0.812
LWAC	0.809

10 Am meisten negativ korreliert
SQBG	-0.875
TCAC	-0.873
TCACU	-0.869
RMRM	-0.85
SVAC	-0.82
TLGT	-0.819

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Provention Bio Inc Korrelation - Währung/Rohstoff

0.13
( neutral )

0.68
( moderate )

0.57
( weak )

0.45
( neutral )

-0.68
( moderate negative )

-0.14
( neutral )

Provention Bio Inc Finanzdaten

Annual	2022
Umsatz:	$12.90M
Bruttogewinn:	$12.38M (96.03 %)
EPS:	$-1.520

FY	2022
Umsatz:	$12.90M
Bruttogewinn:	$12.38M (96.03 %)
EPS:	$-1.520

FY	2021
Umsatz:	$1.40M
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-1.810

FY	2020
Umsatz:	$0.00
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-1.880

Financial Reports:

No articles found.

Provention Bio Inc

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.